182 related articles for article (PubMed ID: 26896780)
1. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
[TBL] [Abstract][Full Text] [Related]
2. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
4. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D
Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
[TBL] [Abstract][Full Text] [Related]
6. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
8. Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants.
Mashkani B; Griffith R; Ashman L
Iran J Basic Med Sci; 2014 Nov; 17(11):867-73. PubMed ID: 25691928
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
[TBL] [Abstract][Full Text] [Related]
10. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
12. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
Nordigården A; Zetterblad J; Trinks C; Gréen H; Eliasson P; Druid P; Lotfi K; Rönnstrand L; Walz TM; Jönsson JI
Br J Haematol; 2011 Oct; 155(2):198-208. PubMed ID: 21848891
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N
Gucký T; Řezníčková E; Radošová Muchová T; Jorda R; Klejová Z; Malínková V; Berka K; Bazgier V; Ajani H; Lepšík M; Divoký V; Kryštof V
J Med Chem; 2018 May; 61(9):3855-3869. PubMed ID: 29672049
[TBL] [Abstract][Full Text] [Related]
14. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
Göring S; Bensinger D; Naumann EC; Schmidt B
ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Weisberg E; Choi HG; Barrett R; Zhou W; Zhang J; Ray A; Nelson EA; Jiang J; Moreno D; Stone R; Galinsky I; Fox E; Adamia S; Kung AL; Gray NS; Griffin JD
Mol Cancer Ther; 2010 Sep; 9(9):2468-77. PubMed ID: 20807780
[TBL] [Abstract][Full Text] [Related]
17. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
[TBL] [Abstract][Full Text] [Related]
18. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
19. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
Smith CC; Lin K; Stecula A; Sali A; Shah NP
Leukemia; 2015 Dec; 29(12):2390-2. PubMed ID: 26108694
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives.
Sobhanifar MA; Mashkani B; Saadatmandzadeh M; Sadeghnia HR; Mousavi SH
Biomed Pharmacother; 2018 Dec; 108():893-905. PubMed ID: 30372901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]